Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Inhibitor + 125I Seeds for Extrahepatic HCC Metastases
NCT06991907Completed
- Start
- Jan 2020
- Primary completion
- Mar 2025
- Countries
- 1
01
Overview
Open-label trial (2 arms). Primary endpoint: Progression-Free Survival up to 62 months. Started Jan 2020; status: completed.
Beyond the preview
Go deeper on NCT06991907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06991907.